ubiquitinlik
protein
conjug
protein
isgyl
strongli
induc
type
interferon
influenza
b
viru
encod
nonstructur
protein
bind
human
provid
appropri
model
determin
isgyl
affect
viru
replic
human
cell
use
recombin
viru
encod
protein
defect
bind
show
counteract
isgylationmedi
antivir
activ
bind
sequest
isgyl
viral
protein
primarili
isgyl
viral
nucleoprotein
np
infect
cell
isgyl
np
sequest
mutant
act
dominantneg
inhibitor
oligomer
abund
unconjug
np
consequ
format
viral
ribonucleoprotein
catalys
viral
rna
synthesi
inhibit
caus
decreas
viral
protein
synthesi
viru
replic
verifi
isgyl
np
larg
respons
inhibit
viral
rna
synthesi
gener
recombin
virus
lack
known
isgyl
site
np
ubiquitinlik
protein
ubl
highli
induc
interferon
ifn
ab
produc
infect
human
cell
viral
bacteri
pathogen
compris
two
ubl
domain
connect
short
fiveamino
acid
linker
unlik
ubiquitin
sequenc
vari
speci
coval
conjug
via
ctermin
lrlrgg
sequenc
target
protein
sequenti
action
three
enzym
also
induc
ifnab
name
ref
conjug
isgyl
revers
ifnabinduc
isopeptidas
cleav
target
protein
find
sever
virus
encod
protein
either
bind
cleav
target
protein
indic
isgyl
andor
free
antivir
function
nonstructur
protein
influenza
b
viru
first
viral
protein
shown
bind
ref
protein
vaccinia
viru
also
interact
ref
sever
virus
nairovirus
arterivirus
sever
acut
respiratori
syndrom
viru
encod
enzym
remov
target
protein
studi
use
knockout
mice
demonstr
isgyl
protect
mice
lethal
infect
sever
virus
includ
influenza
b
virus
isgyl
also
inhibit
influenza
viru
replic
human
tissu
cultur
cell
inhibit
result
isgyl
one
two
lysin
ks
viral
protein
lead
loss
function
exampl
isgyl
k
posit
protein
viru
led
loss
interact
cellular
protein
importina
mediat
nuclear
import
protein
recombin
viru
encod
protein
k
posit
replac
arginin
r
show
tenfold
increas
resist
ifnb
pretreat
compar
wildtyp
wt
viru
indic
isgyl
residu
contribut
ifnb
sensit
influenza
viru
isgyl
viral
protein
consist
find
isgyl
target
newli
synthes
protein
viral
protein
constitut
major
newli
synthes
protein
virusinfect
cell
howev
known
isgyl
constitut
total
protein
infect
cell
lead
loss
function
whole
protein
popul
one
hypothesi
low
level
viral
protein
would
dominantneg
effect
function
unconjug
counterpart
viral
protein
function
oligom
infect
cell
howev
establish
isgyl
protein
isgyl
protein
viru
oper
dominantneg
manner
inhibit
oligomer
unconjug
counterpart
virusinfect
cell
unconjug
free
also
shown
role
host
defens
pathogen
free
extracellular
protect
mice
chikungunya
viru
infect
inhibit
viru
replic
rather
downregul
express
virusinduc
proinflammatori
cytokin
investig
shown
free
extracellular
opposit
effect
name
stimul
ifng
product
human
lymphocyt
lead
increas
cytokin
product
patient
inherit
defici
suscept
mycobacteri
diseas
caus
littl
activ
ifng
indic
requir
antibacteri
immun
contrast
investig
found
cell
patient
suscept
infect
sever
virus
subsequ
studi
patient
cell
deriv
patient
show
intracellular
free
human
cell
downregul
ifnab
respons
bind
stabil
protein
two
activ
remov
isgyl
protein
inhibit
ifn
signal
recent
studi
analys
effect
rel
short
h
treatment
ifnab
follow
h
rest
period
antivir
state
human
cell
level
replic
sever
virus
significantli
higher
cell
increas
replic
attribut
downregul
ifnab
signal
result
stabil
free
investig
also
found
murin
bind
henc
downregul
ifnab
signal
mice
base
result
investig
propos
free
intracellular
well
free
secret
mediat
major
biolog
activ
pathway
human
isgyl
document
role
human
antivir
activ
propos
contrari
previou
studi
establish
isgyl
influenza
viru
protein
caus
inhibit
replic
influenza
viru
human
cell
influenza
b
viru
provid
appropri
model
determin
human
conjug
onto
target
protein
affect
viru
replic
human
cell
unlik
influenza
virus
influenza
b
virus
infect
human
limit
host
rang
might
attribut
protein
influenza
b
viru
bind
human
nonhuman
primat
molecul
demonstr
protein
block
antivir
function
human
nonhuman
primat
cell
structur
human
complex
ntermin
fragment
protein
show
basi
speci
specif
proteinbind
site
includ
two
ntermin
residu
linker
region
specif
human
nonhuman
primat
ref
structur
also
identifi
two
amino
acid
requir
bind
tryptophan
w
posit
glutamin
q
posit
mutant
protein
alanin
substitut
posit
bind
addit
unlik
wt
protein
mutant
protein
inhibit
ifnbinduc
isgyl
assay
transfect
experi
present
studi
gener
recombin
influenza
b
viru
encod
protein
defect
bind
due
alanin
substitut
posit
use
mutant
viru
show
contrari
transfect
result
describ
protein
inhibit
isgyl
influenza
b
virusinfect
cell
instead
protein
bind
sequest
isgyl
viral
protein
especi
isgyl
viral
nucleoprotein
np
demonstr
isgyl
np
protein
sequest
mutant
protein
act
dominantneg
manner
mutant
virusinfect
cell
inhibit
oligomer
abund
unconjug
np
protein
result
format
viral
ribonucleoprotein
rnp
catalys
viral
rna
synthesi
inhibit
caus
decreas
product
viral
rna
viral
protein
henc
decreas
viru
replic
result
establish
ifna
binduc
isgyl
exhibit
potent
antivir
activ
human
cell
determin
whether
inhibit
isgyl
virusinfect
cell
gener
recombin
influenza
b
viru
express
protein
mutat
recombin
viru
denot
mutant
viru
replic
rate
extent
wt
viru
multipl
cycl
growth
human
cell
fig
contrast
mutant
viru
inhibit
greater
extent
wt
viru
cell
pretreat
ifnb
wherea
ifnb
pretreat
cell
reduc
wt
viru
replic
replic
mutant
viru
reduc
tenfold
differ
elimin
short
interf
rna
sirna
control
sirna
fig
differ
sirna
effect
supplementari
b
result
establish
primari
defect
mutant
viru
inabl
counteract
antivir
activ
ifnbinduc
determin
effect
mutant
viru
ifnbinduc
isgyl
cell
treat
ifnb
h
follow
infect
plaqueform
unit
pfu
ml
wt
mutant
viru
durat
dosag
ifnb
pretreat
suffici
induc
free
detect
isgyl
time
viru
infect
consequ
isgyl
occur
viru
infect
enabl
us
determin
effect
wt
mutant
viru
ongo
isgyl
infect
cell
harvest
h
infect
amount
conjug
measur
use
immunoblot
base
previous
publish
cotransfect
experi
would
expect
wt
viru
mutant
viru
would
inhibit
isgyl
surprisingli
observ
opposit
phenotyp
substanti
conjug
produc
wt
virusinfect
cell
mutant
virusinfect
cell
fig
result
lead
unexpect
conclus
protein
inhibit
ifnbinduc
isgyl
influenza
b
virusinfect
cell
isgyl
occur
ifnb
treatment
preced
influenza
b
viru
infect
wt
viru
infect
absenc
ifnb
pretreat
induc
isgyl
lane
clearli
shown
supplementari
fig
isgyl
induc
viru
infect
alon
induc
synthesi
enzym
isgyl
probabl
conjug
enzym
ifnb
ad
infect
wt
virus
inhibit
synthesi
henc
isgyl
supplementari
fig
wildtyp
bind
conjug
viru
infect
analys
interact
protein
conjug
virusinfect
cell
facilit
analysi
gener
two
cell
line
express
either
wt
mutant
contain
ctermin
alaala
instead
glygli
requir
conjug
ntermin
tag
stag
tag
control
promot
cell
line
denot
cell
fig
cell
doubletag
protein
effect
conjug
target
protein
ifnbdepend
manner
fig
case
endogen
larger
amount
conjug
contain
doubletag
produc
wt
virusinfect
cell
virusinfect
cell
fig
sirna
knockdown
enzym
elimin
conjug
verifi
conjug
verif
show
conjug
produc
wt
viru
infect
ifntreat
cell
fig
determin
whether
conjug
wt
virusinfect
cell
bound
protein
cell
extract
cell
infect
wt
viru
fig
lane
viru
fig
lane
immunoprecipit
antibodi
follow
immunoblot
probe
flag
antibodi
fig
result
show
wt
protein
mutant
protein
bind
conjug
identifi
isgyl
target
purifi
conjug
ifnbpretr
wt
virusinfect
cell
sequenti
affin
purif
antiflag
affin
resin
sprotein
agaros
denatur
condit
result
purifi
protein
separ
sdspolyacrylamid
gel
electrophoresi
four
major
band
identifi
colloid
blue
stain
fig
mass
spectrometri
band
show
contain
primarili
viral
protein
specif
np
band
band
matrix
protein
band
base
molecular
weight
np
speci
band
like
np
np
respect
mass
spectrometri
also
identifi
lysin
ks
modifi
three
protein
fig
supplementari
tabl
multipl
ks
np
attach
site
six
ks
np
four
ks
np
figur
show
locat
site
crystal
structur
influenza
b
viru
np
site
locat
near
import
function
region
np
locat
near
tail
loop
mediat
oligomer
locat
close
electroposit
groov
requir
rna
bind
locat
n
terminu
function
nuclear
local
signal
np
np
also
found
ifnbpretr
virusinfect
cell
lower
level
compar
wt
virusinfect
cell
fig
immunoblot
input
cell
extract
detect
isgyl
np
wherea
larg
amount
unconjug
np
detect
show
isgyl
np
compris
minor
fraction
total
np
popul
virusinfect
cell
c
cell
transfect
control
ctrl
sirna
ubel
specif
sirna
h
follow
treatment
iu
ml
human
ifnb
h
cell
infect
pfu
per
cell
either
wt
mutant
viru
h
cell
extract
analys
immunoblot
probe
flag
ab
mut
wt
cell
treat
iu
ml
human
ifnb
h
infect
pfu
per
cell
wt
viru
h
denatur
cell
extract
subject
doubleaffin
purif
use
antiflag
agaros
sprotein
agaros
purifi
protein
detect
silver
stain
sd
page
e
cell
extract
analys
lane
panel
c
instead
immunoprecipit
ab
immunoprecipit
analys
immunoblot
probe
flag
ab
ab
mutant
protein
first
approach
identifi
isgyl
viral
protein
respons
defect
determin
step
viru
replic
inhibit
isgyl
virusinfect
cell
ifnb
pretreat
cell
infect
either
wt
viru
high
multipl
infect
cell
therebi
gener
singl
cycl
viru
replic
ifnb
treatment
cell
transfect
sirna
indic
fig
cell
transfect
control
sirna
lane
amount
viral
haemagglutinin
ha
np
protein
produc
cell
infect
viru
lower
amount
cell
infect
wt
viru
transfect
sirna
lane
increas
isgyl
reduc
product
ha
np
protein
virusinfect
cell
littl
effect
product
viral
protein
wt
virusinfect
cell
second
sirna
effect
supplementari
fig
contrast
level
protein
show
decreas
virusinfect
cell
like
explan
lack
effect
protein
synthesi
present
supplementari
fig
effect
knockdown
ha
np
product
virusinfect
cell
revers
cotransfect
sirna
lane
sirna
lane
either
elimin
conjug
establish
effect
caus
augment
isgyl
result
consist
recent
studi
establish
provir
activ
via
deconjug
ref
free
remain
knockdown
inhibit
viral
protein
product
virusinfect
cell
lane
conclud
isgyl
protein
free
intracellular
respons
inhibit
viral
protein
product
virusinfect
cell
determin
whether
isgyl
act
level
viral
rna
synthesi
measur
level
sever
mrna
mrna
ha
na
neuraminidas
np
correspond
viral
rna
vrna
wt
virusand
virusinfect
cell
use
quantit
revers
transcript
pcr
rtpcr
cell
sirnasilenc
level
mrna
lower
virusinfect
cell
wt
virusinfect
cell
fig
left
panel
mirror
differ
level
viral
protein
condit
fig
lane
reduct
vrna
level
consist
larger
fig
right
panel
cell
well
sirnasilenc
differ
mrna
vrna
level
wt
virusinfect
cell
reduc
fig
similar
effect
viral
protein
product
fig
lane
case
knockdown
lead
small
signific
increas
less
twofold
mrna
vrna
product
wt
virusinfect
cell
also
knock
fig
small
increas
may
due
augment
level
isgyl
viral
protein
caus
knockdown
result
augment
wt
protein
might
capabl
sequest
isgyl
viral
protein
lead
small
amount
antivir
activ
caus
free
isgyl
viral
protein
also
determin
whether
mrna
vrna
product
reduc
virusinfect
cell
express
endogen
level
isgyl
cell
transfect
control
sirna
fig
reduct
mrna
level
mirror
differ
level
viral
protein
produc
wt
virus
condit
compar
fig
left
panel
fig
lane
reduct
vrna
level
larger
fig
right
panel
presum
account
fourfold
reduct
viru
replic
infect
condit
supplementari
fig
conclud
isgyl
respons
inhibit
viral
rna
product
virusinfect
cell
lead
inhibit
product
viral
protein
primari
target
isgyl
therebi
explain
level
isgyl
reduc
virusinfect
cell
isgyl
np
inhibit
oligomer
unconjug
np
three
isgyl
viral
protein
sequest
mutant
protein
isgyl
np
like
respons
inhibit
viral
rna
synthesi
np
integr
compon
doublehel
viral
rnp
catalys
viral
rna
synthesi
viral
rnp
compris
singl
trimer
viral
polymeras
bind
end
vrna
negativesens
segment
crna
positivesens
segment
multipl
np
protein
coat
entireti
rest
vrna
crna
chain
format
vrnp
requir
np
oligomer
along
vrna
crna
chain
process
tail
loop
np
molecul
insert
caviti
adjac
np
molecul
even
small
amount
isgyl
np
molecul
produc
virusinfect
cell
could
disrupt
np
oligomer
dominantneg
manner
loop
insert
site
block
ks
fig
exampl
isgyl
np
might
bind
unconjug
np
end
nascent
np
oligom
tail
loop
unconjug
np
abl
insert
pocket
isgyl
np
block
ks
contrast
tail
loop
isgyl
np
might
block
ks
insert
pocket
unconjug
incom
np
therebi
termin
oligomer
inde
np
protein
influenza
viru
mutant
defect
tail
loop
intact
insert
caviti
vice
versa
shown
inhibit
wt
npmediat
vrnp
format
dominantneg
manner
test
hypothesi
describ
assembl
vrnp
infect
occur
nucleu
determin
whether
nuclear
vrnp
format
inhibit
isgyl
np
protein
virusinfect
cell
compar
wt
virusinfect
cell
first
devis
method
separ
virusinfect
cell
cytoplasm
nuclear
fraction
cell
pretreat
ifnb
infect
either
wt
viru
cell
extract
collect
h
infect
separ
cytoplasm
nuclear
fraction
fig
indic
nuclear
marker
cytoplasm
bactin
marker
appar
cross
contamin
cytoplasm
nuclear
fraction
major
protein
local
cytoplasm
fraction
cell
infect
either
viru
consist
previous
publish
immunofluoresc
result
show
shift
protein
nucleu
cytoplasm
cours
infect
np
locat
cytoplasm
nucleu
determin
whether
nuclear
vrnp
format
inhibit
virusinfect
cell
cell
pretreat
sirna
ifnb
infect
wt
viru
nuclear
extract
analys
glycerol
gradient
centrifug
separ
vrnp
free
np
molecul
fig
immunoblot
probe
np
antibodi
show
nuclear
np
wt
virusinfect
cell
sediment
posit
vrnp
fraction
contrast
np
virusinfect
cell
sediment
posit
vrnp
predominantli
posit
smaller
size
vrnp
fraction
consist
defect
vrnp
assembl
virusinfect
cell
treat
sirna
nuclear
vrnp
format
restor
level
compar
wt
virusinfect
cell
verifi
nuclear
vrnp
assembl
defect
virusinfect
cell
devis
treatment
condit
control
sirna
shorter
ifn
treatment
result
product
approxim
equal
amount
nuclear
np
wt
viru
virusinfect
cell
shown
fig
condit
nuclear
np
wt
virusinfect
cell
vrnp
wherea
virusinfect
cell
total
np
free
expens
np
vrnp
confirm
vrnp
format
virusinfect
cell
inhibit
rel
wt
virusinfect
cell
model
termin
np
oligomer
shown
fig
predict
isgyl
nuclear
np
molecul
virusinfect
cell
would
associ
long
chain
unconjug
np
molecul
termin
np
oligom
degrad
determin
whether
case
use
cell
purifi
isgyl
protein
doubleaffin
select
cytoplasm
nuclear
fraction
cell
pretreat
sirna
ifnb
follow
infect
wt
viru
purif
perform
nondenatur
condit
preserv
interact
isgyl
np
unconjug
np
immunoblot
probe
np
antibodi
fig
show
small
amount
isgyl
np
nucleu
virusinfect
cell
predomin
np
associ
larg
excess
unconjug
np
predict
termin
model
presenc
two
isgyl
site
ntermin
region
np
contain
nuclear
local
signal
fig
provid
definit
evid
isgyl
np
inhibit
viral
rna
synthesi
gener
recombin
virus
express
np
protein
one
np
isgyl
site
elimin
ktor
mutat
determin
whether
elimin
isgyl
site
reliev
inhibit
vrna
synthesi
virusinfect
cell
consequ
identifi
set
np
ktor
mutat
posit
substanti
reliev
ifnbmedi
inhibit
vrna
synthesi
virusinfect
cell
elimin
four
np
isgyl
site
increas
ha
vrna
product
virusinfect
cell
level
wt
virusinfect
cell
fig
sirna
knockdown
increas
ha
vrna
product
virusinfect
cell
level
cell
infect
viru
contain
four
ktor
mutat
supplementari
fig
demonstr
differ
vrna
level
due
isgyl
four
k
residu
result
confirm
isgyl
np
larg
respons
inhibit
viral
rna
synthesi
virusinfect
cell
although
transfect
assay
indic
protein
influenza
b
viru
inhibit
isgyl
present
studi
demonstr
isgyl
inhibit
protein
influenza
b
virusinfect
cell
instead
protein
bind
sequest
isgyl
viral
protein
use
recombin
viru
express
mutant
protein
defect
bind
elucid
major
consequ
failur
mutant
protein
bind
isgyl
viral
protein
infect
cell
show
viral
np
protein
primari
target
isgyl
demonstr
isgyl
np
protein
bound
mutant
protein
although
small
percentag
total
np
protein
mutant
virusinfect
cell
act
dominantneg
manner
termin
oligomer
unconjug
np
molecul
result
incomplet
np
oligom
contain
isgyl
np
first
demonstr
isgyl
viral
protein
act
dominantneg
inhibitor
oligomer
much
abund
unconjug
counterpart
virusinfect
cell
np
oligomer
along
viral
rna
chain
requir
format
viral
rnp
catalys
viral
rna
synthesi
inhibit
np
oligomer
isgyl
np
inhibit
format
viral
rnp
henc
inhibit
viral
rna
synthesi
conclus
support
find
elimin
subset
isgyl
site
np
significantli
reliev
inhibit
viral
rna
synthesi
inhibit
viral
rna
product
result
inhibit
synthesi
viral
protein
primari
target
isgyl
explain
reduc
level
isgyl
virusinfect
cell
howev
result
rule
possibl
two
viral
isgyl
target
also
role
inhibit
viru
replic
nevertheless
identifi
sequestr
isgyl
viral
protein
novel
viral
countermeasur
ifnabinduc
isgyl
establish
isgyl
exhibit
potent
antivir
activ
human
cell
np
protein
influenza
b
virus
oligomer
rna
templat
requir
tail
loop
np
molecul
insert
caviti
adjac
np
molecul
previou
studi
np
protein
influenza
viru
npa
show
npa
mutant
defect
either
loop
insert
site
could
function
domin
neg
mutant
inhibit
oligomer
wt
npa
therebi
inhibit
viral
rna
synthesi
catalys
viral
rnp
would
expect
dominantneg
action
similar
mutant
influenza
b
viru
np
npb
molecul
light
high
structur
similar
npa
npb
protein
fact
result
indic
isgyl
npb
protein
probabl
imped
function
loop
isgyl
locat
base
loop
one
four
isgyl
function
dominantneg
inhibit
viral
rna
synthesi
result
consist
model
shown
fig
supplementari
fig
dominantneg
inhibit
npb
polymer
isgyl
npb
howev
result
indic
isgyl
site
differ
region
npb
loop
insert
site
also
appar
function
inhibit
viral
rna
synthesi
name
locat
rnabind
surfac
locat
bodi
domain
shown
mutant
npa
protein
defect
rna
bind
still
recruit
viral
rna
templat
interact
wt
np
consequ
isgyl
npb
molecul
defect
rna
bind
might
recruit
nascent
np
oligom
wt
np
one
possibl
consequ
incorpor
isgyl
npb
molecul
destabil
interact
np
oligom
viral
rna
templat
function
impact
isgyl
known
note
elimin
four
isgyl
site
larg
complet
rescu
isgylationmedi
inhibit
viral
rna
synthesi
suggest
isgyl
k
residu
np
may
also
impact
viral
rna
synthesi
preferenti
target
np
protein
isgyl
influenza
b
virusinfect
cell
differ
isgyl
target
cell
infect
influenza
viru
primari
viral
target
cell
infect
influenza
viru
protein
isgyl
npa
protein
detect
differ
influenza
b
virus
attribut
least
part
fact
influenza
virus
encod
protein
analog
influenza
b
viru
protein
directli
counter
antivir
action
isgyl
consequ
like
influenza
viru
influenza
b
viru
would
select
pressur
develop
mechan
circumv
antivir
activ
isgyl
note
other
total
lysin
k
content
protein
sever
influenza
b
virus
higher
sever
influenza
virus
percentag
ks
npb
protein
influenza
b
virus
twofold
greater
npa
protein
influenza
virus
isol
human
supplementari
fig
none
npa
protein
contain
ks
four
site
correspond
isgyl
site
npb
function
dominantneg
inhibit
viral
rna
synthesi
supplementari
fig
differ
influenza
b
virus
consist
hypothesi
isgylationdriven
evolut
influenza
virus
led
replac
substanti
number
ks
encod
protein
rs
therebi
elimin
potenti
modif
fact
isgylationdriven
evolut
like
occur
recent
virus
previous
show
k
posit
protein
primari
target
isgyl
cell
infect
viru
isol
replac
k
r
reliev
ifnb
sensit
viru
ktor
chang
occur
protein
virus
isol
demonstr
virus
isol
acquir
mutat
natur
essenti
elimin
suscept
inhibit
ifnbinduc
isgyl
regul
human
immun
respons
multipl
way
two
form
insid
human
cell
free
conjug
target
protein
recent
studi
found
free
could
provir
interact
therebi
stabil
downregul
ifnab
signal
subsequ
hypothes
main
function
system
human
cell
inhibit
inflammatori
respons
via
free
wherea
isgyl
primarili
function
regul
level
free
exhibit
signific
antivir
activ
howev
previous
show
isgyl
inhibit
influenza
virus
present
studi
clearli
establish
ifnbinduc
isgyl
potent
inhibitor
influenza
b
viru
replic
protect
effect
viral
protein
elimin
free
signific
role
inhibit
shown
demonstr
free
remain
sirna
knockdown
enzym
inhibit
viral
protein
product
base
present
studi
appar
isgylationdriven
evolut
influenza
virus
think
reason
propos
ifnabinduc
isgyl
rel
ancient
antivir
activ
virus
overcom
either
action
specif
viral
protein
like
block
antivir
effect
isgyl
andor
isgylationdriven
evolut
ktor
mutat
andor
amino
acid
chang
elimin
isgyl
site
virus
cell
mutant
virus
gener
revers
genet
method
employ
eightplasmid
bidirect
transcript
system
describ
hoffmann
et
al
viru
stock
grown
fertil
chicken
egg
viru
titer
determin
use
plaqu
assay
mdck
cell
eight
segment
recombin
virus
sequenc
mdck
cell
obtain
american
type
cultur
collect
atcc
maintain
dulbecco
modifi
eagl
medium
invitrogen
supplement
fetal
bovin
serum
establish
ifnbinduc
cell
line
plasmid
construct
insert
vector
kpnixbai
dna
fragment
compos
sequenc
link
promot
element
end
dna
fragment
product
pcrmediat
ligat
two
smaller
fragment
one
fragment
contain
promot
sequenc
base
amplifi
hela
genom
dna
fragment
encod
gener
pcrmediat
addit
sequenc
sequenc
construct
plasmid
mg
cotransfect
mg
linear
puromycin
select
marker
clontech
cell
select
medium
contain
mg
ml
puromycin
individu
clone
select
expand
clone
show
strongest
ifnbdepend
induct
well
conjug
use
viru
infect
experi
control
ifnbinduc
cell
line
gener
use
procedur
sirna
antibodi
sirna
ontarget
plu
sirna
purchas
thermo
scientif
gene
three
differ
sirna
initi
test
one
highest
silenc
effici
indic
immunoblot
chosen
subsequ
experi
sens
sequenc
sirna
follow
cugcauaucu
control
sirna
use
ontarget
plu
nontarget
sirna
exclud
offtarget
effect
also
employ
addit
sirna
silenc
sens
sequenc
sirna
follow
transfect
sirna
carri
use
lipofectamin
rnaimax
reagent
invitrogen
use
final
concentr
sirna
nm
nm
sirna
two
sirna
transfect
togeth
commerci
antibodi
ab
use
antiflag
mous
ab
sigma
dilut
mous
ab
influenza
b
viru
np
southern
biotech
dilut
mous
ab
influenza
b
viru
protein
southern
biotech
dilut
rabbit
ab
abgent
antibactin
ab
sigma
dilut
rabbit
antibodi
cell
signal
dilut
rabbit
antibodi
parp
cell
signal
dilut
ab
specif
human
kindli
provid
earnest
borden
express
viral
ha
protein
detect
use
serum
ferret
subject
influenza
b
viru
infect
kindli
provid
jonathan
mcculler
gener
antibodi
specif
ctermin
domain
influenza
strain
express
purifi
bacteria
kindli
provid
gaetano
montelion
sent
harlan
bioproduct
scienc
indianapoli
rabbit
polyclon
antibodi
product
quantit
western
blot
perform
use
nih
imagej
softwar
origin
western
blot
scan
fig
provid
supplementari
fig
assay
viru
replic
viral
rna
protein
synthesi
multipl
cycl
growth
cell
infect
plaqueform
unit
pfu
per
cell
wt
mutant
viru
follow
incub
serumfre
optimem
medium
supplement
mg
ml
nacetyl
trypsin
aliquot
medium
taken
interv
approxim
h
viru
titer
determin
use
plaqu
assay
mdck
cell
singlecycl
viru
replic
cell
infect
pfu
per
cell
wt
mutant
viru
incub
serumfre
optimem
medium
indic
cell
pretreat
intern
unit
iu
ml
recombin
human
ifnb
avonex
biogen
inc
h
viru
infect
sirna
knockdown
experi
sirna
transfect
cell
h
ifnb
treatment
h
viru
infect
cell
collect
analys
use
either
immunoblot
realtim
quantit
rtpcr
immunoblot
cell
lyse
highsalt
ripa
buffer
mm
trishcl
mm
nacl
mm
edta
sodium
deoxychol
sd
supplement
proteas
inhibitor
unit
ml
benzonas
sigma
sonic
clear
centrifug
extract
analys
immunoblot
indic
ab
rtpcr
analysi
cell
harvest
trizol
reagent
invitrogen
total
rna
purifi
directzol
rna
miniprep
kit
zymo
research
revers
transcript
reaction
carri
use
transcriptor
revers
transcriptas
roch
either
oligo
dt
primer
mrna
influenza
b
viru
genespecif
primer
vrna
realtim
pcr
carri
viia
realtim
pcr
system
invitrogen
measur
ha
na
np
rna
faststart
univers
probe
master
rox
roch
univers
probe
librari
roch
use
human
actb
beta
actin
endogen
control
appli
biosystem
use
intern
control
univers
probe
roch
use
ha
np
na
measur
ns
rna
suitabl
univers
probe
librari
roch
sybr
green
base
quantit
pcr
melt
curv
analysi
employ
use
power
sybr
master
mix
appli
biosystem
method
also
appli
assay
np
actin
rna
experi
data
analys
use
compar
deltadelta
ct
method
primer
sequenc
provid
supplementari
tabl
coimmunoprecipit
analysi
interact
cell
first
treat
indic
sirna
h
follow
h
treatment
iu
ml
human
ifnb
infect
pfu
per
cell
either
wt
mutant
viru
cell
harvest
h
infect
extract
cold
ripa
lysi
buffer
mm
trishcl
ph
mm
nacl
mm
mgcl
sodium
deoxychol
sd
supplement
proteas
inhibitor
unit
ml
benzonas
sigma
brief
sonic
lysat
clear
centrifug
min
protein
concentr
extract
measur
use
dc
protein
assay
biorad
aliquot
extract
contain
mg
protein
use
coimmunoprecipit
extract
preclear
incub
ml
dynabead
protein
g
invitrogen
h
incub
h
ul
dynabead
protein
g
preabsorb
mg
ab
bead
wash
five
time
ripa
buffer
bound
protein
elut
sd
sampl
buffer
analys
immunoblot
probe
flag
ab
cell
treat
iu
ml
human
ifnb
h
follow
infect
pfu
per
cell
wt
viru
h
infect
cell
lyse
sd
denatur
lysi
buffer
mm
trishcl
ph
sd
glycerol
room
temperatur
lysat
sonic
mix
nine
volum
cold
dilut
buffer
ph
triton
mm
nacl
triton
incub
antiflag
sigma
bead
h
flagtag
protein
elut
bead
mg
ml
flag
peptid
eluat
incub
sprotein
agaros
bead
emd
millipor
h
extens
wash
bead
dilut
buffer
protein
elut
use
sd
sampl
buffer
subject
sdspolyacrylamid
gel
electrophoresi
gel
analys
colloid
blue
stain
four
major
protein
band
detect
use
colloid
blue
stain
cut
sent
taplin
biolog
mass
spectrometri
facil
harvard
medic
school
mass
spectrometri
analysi
protein
band
subject
ingel
trypsin
digest
treat
iodoacetamid
alkyl
free
cystein
prevent
alkyl
lysin
residu
alkyl
reaction
carri
room
temperatur
dark
protein
peptid
extract
gel
analys
qeactiv
mass
spectromet
high
resolut
ms
msm
data
gener
data
search
human
protein
databas
influenza
b
protein
assembl
sequest
targetdecoy
strategi
filter
data
fals
discoveri
rate
qualiti
identifi
digli
site
assign
base
pass
fals
discoveri
rate
threshold
verifi
manual
inspect
spectrum
assay
vrnp
format
nucleu
infect
cell
cell
cm
dish
transfect
indic
sirna
h
follow
treatment
iu
ml
human
ifnb
h
infect
pfu
per
cell
either
wt
mutant
viru
h
infect
cell
collect
trypsin
lowspe
centrifug
cell
pellet
extract
yield
cytoplasm
nuclear
fraction
describ
fodor
et
al
minor
modif
briefli
cell
pellet
lyse
min
ice
ml
buffer
nonidet
mm
trishcl
mm
kcl
mm
edta
mm
dithiothreitol
dtt
supplement
proteas
inhibitor
nuclei
pellet
centrifug
min
wash
ml
buffer
resuspend
ml
buffer
b
nonidet
mm
trishcl
mm
nacl
mm
edta
mm
dtt
supplement
proteas
inhibitor
ml
rnaseout
invitrogen
nuclear
extract
clear
twice
centrifug
min
ml
clarifi
nuclear
extract
mg
load
onto
discontinu
glycerol
gradient
compris
ml
glycerol
prepar
glycerol
gradient
buffer
mm
trishcl
ph
mm
nacl
mm
edta
mm
dtt
supplement
proteas
inhibitor
unit
per
ml
rnaseout
ultracentifug
carri
beckman
rotor
h
fourteen
fraction
ml
manual
collect
top
bottom
gradient
analys
np
immunoblot
assay
associ
isgyl
np
free
np
cytoplasm
nuclear
fraction
sirnatransfect
ifnpretr
virusinfect
cell
prepar
use
procedur
describ
assay
vrnp
format
except
rnaseout
replac
benzonas
presenc
mgcl
remov
rna
result
fraction
subject
doubleaffin
select
analys
immunoblot
probe
np
antibodi
data
avail
author
declar
data
support
find
studi
avail
within
articl
supplementari
inform
file
avail
author
upon
request
